The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty
Open accessAbstract
BACKGROUND: Platelets are believed to play a part in the ischemic complications of coronary angioplasty, such as abrupt closure of the coronary vessel during or soon after the procedure. Accordingly, we evaluated the effect of a chimeric monoclonal-antibody Fab fragment (c7E3 Fab) directed against the platelet glycoprotein IIb/IIIa receptor, in patients undergoing angioplasty who were at high risk for ischemic complications. This receptor is the final common pathway for platelet aggregation. METHODS: In a prospective, randomized, double-blind trial, 2099 patients treated at 56 centers received a bolus and an infusion of placebo, a bolus of c7E3 Fab and an infusion of placebo, or a bolus and an infusion of c7E3 Fab. They were scheduled to undergo coronary angioplasty or atherectomy in high-risk clinical situations involving severe unstable angina, evolving acute myocardial infarction, or high-risk coronary morphologic characteristics. The primary study end point consisted of any of the following: death, nonfatal myocardial infarction, unplanned surgical revascularization, unplanned repeat percutaneous procedure, unplanned implantation of a coronary stent, or insertion of an intraaortic balloon pump for refractory ischemia. The numbers of end-point events were tabulated for 30 days after randomization. RESULTS: As compared with placebo, the c7E3 Fab bolus and infusion resulted in a 35 percent reduction in the rate of the primary end point (12.8 vs. 8.3 percent, P = 0.008), whereas a 10 percent reduction was observed with the c7E3 Fab bolus alone (12.8 vs. 11.5 percent, P = 0.43). The reduction in the number of events with the c7E3 Fab bolus and infusion was consistent across the end points of unplanned revascularization procedures and nonfatal myocardial infarction. Bleeding episodes and transfusions were more frequent in the group given the c7E3 Fab bolus and infusion than in the other two groups. CONCLUSIONS: Ischemic complications of coronary angioplasty and atherectomy were reduced with a monoclonal antibody directed against the platelet IIb/IIIa glycoprotein receptor, although the risk of bleeding was increased.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yusuf, S. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470010097038 · Cited by 1,014
Cited by
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
The clinical implications of endothelial dysfunction
Widlansky, M. E., Gokce, N., Keaney, J. F., & Vita, J. A. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00994-x · Cited by 1,749
Prevalence of Conventional Risk Factors in Patients With Coronary Heart Disease
Khot, U. N. (2003) · JAMA · doi:10.1001/jama.290.7.898 · Cited by 1,494
Contradicted and Initially Stronger Effects in Highly Cited Clinical Research
Ioannidis, J. P. A. (2005) · JAMA · doi:10.1001/jama.294.2.218 · Cited by 1,465
Gorbet, M. B., & Sefton, M. V. (2004) · Biomaterials · doi:10.1016/j.biomaterials.2004.01.023 · Cited by 1,347
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000133 · Cited by 1,254
Lincoff, A. M., Bittl, J. A., Harrington, R. A., Feit, F., Kleiman, N. S., Jackman, J. D., Sarembock, I. J., Cohen, D. J., Spriggs, D., Ebrahimi, R., et al. (2003) · JAMA · doi:10.1001/jama.289.7.853 · Cited by 1,162
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000134 · Cited by 1,059
Boersma, E., Harrington, R. A., Moliterno, D. J., White, H., Théroux, P., Van de Werf, F., de Torbal, A., Armstrong, P. W., Wallentin, L. C., Wilcox, R. G., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07442-1 · Cited by 991
Patrono, C., Coller, B., Dalen, J. E., Fitz Gerald, G. A., Fuster, V., Gent, M., Hirsh, J., & Roth, G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.39s · Cited by 963
Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00889-5 · Cited by 963
van der Giessen, W. J., Lincoff, A. M., Schwartz, R. S., van Beusekom, H. M. M., Serruys, P. W., Holmes, D. R., Ellis, S. G., & Topol, E. J. (1996) · Circulation · doi:10.1161/01.cir.94.7.1690 · Cited by 852
Fuster, V (1994) · Circulation · doi:10.1161/01.cir.90.4.2126 · Cited by 848
Brener, S. J., Barr, L. A., Burchenal, J. E. B., Katz, S., George, B. S., Jones, A. A., Cohen, E. D., Gainey, P. C., White, H. J., Cheek, H. B., et al. (1998) · Circulation · doi:10.1161/01.cir.98.8.734 · Cited by 722
Writing Committee Members, Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31823a5596 · Cited by 632
Smith, S. C., Dove, J. T., Jacobs, A. K., Kennedy, J. W., Kereiakes, D., Kern, M. J., Kuntz, R. E., Popma, J. J., Schaff, H. V., Williams, D. O., et al. (2001) · Circulation · doi:10.1161/01.cir.103.24.3019 · Cited by 608
Cellular origin and procoagulant properties of microparticles in meningococcal sepsis
Nieuwland, R., Berckmans, R. J., McGregor, S., Böing, A. N., Th. M. Romijn, F. P. H., Westendorp, R. G. J., Hack, C. E., & Sturk, A. (2000) · Blood · doi:10.1182/blood.v95.3.930.003k46_930_935 · Cited by 574
Weitz, J. I., Eikelboom, J. W., & Samama, M. M. (2012) · Chest · doi:10.1378/chest.11-2294 · Cited by 527
Heeschen, C., Hamm, C. W., Bruemmer, J., & Simoons, M. L. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00581-7 · Cited by 414
2011 Writing Group Members, Wright, R. S., Anderson, J. L., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., Jneid, H., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820f2f3e · Cited by 357
Clinical Aspects of Platelet Inhibitors and Thrombus Formation
Meadows, T. A., & Bhatt, D. L. (2007) · Circulation Research · doi:10.1161/01.res.0000264509.36234.51 · Cited by 351
Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery
Kim, B., Park, J., & Sailor, M. J. (2019) · Advanced Materials · doi:10.1002/adma.201903637 · Cited by 298
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.028 · Cited by 283
Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics.
Coller, B. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119307 · Cited by 263
Management of coronary artery disease: therapeutic options in patients with diabetes
Hammoud, T., Tanguay, J.-F., & Bourassa, M. G. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00732-4 · Cited by 256
Palmer, S. C., Di Micco, L., Razavian, M., Craig, J. C., Perkovic, V., Pellegrini, F., Copetti, M., Graziano, G., Tognoni, G., Jardine, M., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-6-201203200-00007 · Cited by 204
Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox)
Gurm, H. S., Brennan, D. M., Booth, J., Tcheng, J. E., Lincoff, A. M., & Topol, E. J. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02384-6 · Cited by 194
Pathophysiology and clinical significance of atherosclerotic plaque rupture
Gutstein, D. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(98)00322-8 · Cited by 151
Atherosclerosis and thrombosis: insights from large animal models
Vilahur, G., Padro, T., & Badimon, L. (2011) · BioMed Research International · doi:10.1155/2011/907575 · Cited by 118
Principles From Clinical Trials Relevant to Clinical Practice: Part I
Califf, R. M., & DeMets, D. L. (2002) · Circulation · doi:10.1161/01.cir.0000023260.78078.bb · Cited by 108
Nitric Oxide Donors: A Continuing Opportunity in Drug Design
Hanson, S. R., Hutsell, T. C., Keefer, L. K., Mooradian, D. L., & Smith, D. J. (1995) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)61099-6 · Cited by 47
(2025) · doi:10.1016/j.antiviral.2025.106235 · Cited by 1
Metadata
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1994-04-07
- Volume
- 330
- Issue
- 14
- Pages
- 956-961
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3022148767
- Cited by
- 2,589
- References
- 1
- FWCI
- 120.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
